Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies

Seong Cho,Bruce Tan,Noam Cohen,Jody Tversky,Elina Toskala,Scott Nash,Haixing Zhang,Shahid Siddiqui,Asif Khan,Juby Jacob-Nara,Paul Rowe,Yamo Deniz

doi:10.1016/j.jaci.2021.12.483

Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies

Seong Cho, Bruce Tan + Show 10 more

https://doi.org/10.1016/j.jaci.2021.12.483

Copy DOI

Journal: Journal of Allergy and Clinical Immunology

Publication Date: Feb 1, 2022

Affiliation: University of South Florida, Northwestern University, University of Pennsylvania, Johns Hopkins Medicine, Johns Hopkins University, Thomas Jefferson University, Regeneron (United States), Sanofi (France), Sanofi (United States)

#Chronic Rhinosinusitis With Nasal Polyps #Outcomes In Chronic Rhinosinusitis + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Dupilumab 300 mg q2w significantly improved endoscopic, radiographic, clinical, and patient-reported outcomes as well as health-related quality of life in patients with CRSwNP in the SINUS-24 and SINUS-52 studies (NCT02912468/NCT02898454). This post-hoc analysis investigated dupilumab’s efficacy in the SINUS studies according to baseline body mass index (BMI) and weight.

Full Text